Stock Research: Fisher & Paykel Healthcare

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Fisher & Paykel Healthcare

NZSE:FPH NZFAPE0001S2
88
  • Value
    72
  • Growth
    81
  • Safety
    Safety
    14
  • Combined
    57
  • Sentiment
    45
  • 360° View
    360° View
    88
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Fisher & Paykel Healthcare Corporation Limited designs, manufactures, and markets products and systems for use in acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea. The company operates in the medical device industry, with products for hospital and homecare settings. It sells its products in over 120 countries worldwide, including Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, and India. In the last fiscal year, the company had a market cap of $12,544 million, profits of $722 million, revenue of $1,148 million, and 7506 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 88 (better than 88% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Fisher & Paykel Healthcare are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Fisher & Paykel Healthcare. The consolidated Growth Rank has a good rank of 81, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 81% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 72 which means that the company has a financing structure that is safer than 72% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 14 which means that the share price of Fisher & Paykel Healthcare is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 86% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 45, which means that professional investors are more pessimistic about the stock than for 55% of alternative investment opportunities. ...read more

more
Index
ASX 100
ASX 200
ASX 300
Human Rights
SDG 12
SDG 3
SDG 8
NZSX 50
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
14 13 26 19
Growth
81 99 49 33
Safety
Safety
72 75 73 59
Sentiment
45 46 58 37
360° View
360° View
88 78 59 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
13 7 3 19
Opinions Change
50 54 83 50
Pro Holdings
n/a 41 59 40
Market Pulse
85 83 83 69
Sentiment
45 46 58 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
14 13 26 19
Growth
81 99 49 33
Safety Safety
72 75 73 59
Combined
57 79 60 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
13 11 14 19
Price vs. Earnings (P/E)
5 3 7 13
Price vs. Book (P/B)
5 7 7 9
Dividend Yield
39 44 55 45
Value
14 13 26 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
83 77 78 10
Profit Growth
75 70 45 10
Capital Growth
35 98 19 95
Stock Returns
53 91 51 51
Growth
81 99 49 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
73 67 77 72
Refinancing
18 22 20 24
Liquidity
100 100 84 83
Safety Safety
72 75 73 59

Similar Stocks

Discover high‑ranked alternatives to Fisher & Paykel Healthcare and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Samsung Engineering

KOSE:A028050
Country: South Korea
Industry: Construction & Engineering
Size: Medium
Full Stock Analysis

KT

KOSE:A030200
Country: South Korea
Industry: Integrated Telecommunication
Size: Large
Full Stock Analysis

AMOREPACIFIC

KOSE:A002790
Country: South Korea
Industry: Personal Products
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.